Risk Factors for Mortality in Hemodialysis Patients: Two-Year Follow-Up Study

Table 2

Baseline values in ESRD patients under HD therapy for variables in which significant differences were found when the patients were divided in two groups (alive or dead 2 years later).

	Alive at followup (135 patients)	Dead during followup (35 patients)	P
Biochemical and dialysis markers
Calcium, mg/dL	8.70 (8.20–9.10)	8.40 (8.00–8.90)	0.046
Calcium phosphorus product	38.6 (31.4–46.5)	35.8 (29.2–39.2)	0.025
Creatinine, mg/dL	8.63±2.86	6.45±2.10	<0.001
Ultrafiltration volume, L	2.47±0.85	2.29±1.22	0.037
Darbopoeitin-α, μg/kg/week	0.40 (0.77–0.66)	0.87 (0.36–1.47)	<0.001
Hematological data
RDW, %	14.5±1.43	16.9±2.32	<0.001
Iron metabolism markers
Transferrin, mg/dL	187.6±34.1	172.5±41.6	0.050
Transferrin saturation, %	15.8 (12.3–19.7)	13.5 (9.67–19.1)	0.032
Inflammatory markers
IL-6, pg/mL	2.21 (1.37–3.60)	4.27 (2.10–6.57)	<0.001
CRP, mg/dL	3.93 (2.09–9.73)	14.9 (5.15–30.4)	<0.001
Lipid profile
Triglyceride, mg/dL	120.0 (95.0–180.0)	103.0 (82.0–125.0)	0.015
VLDL, mg/dL	24.0 (18.8–36.0)	20.6 (16.4–25.0)	0.021
Apo A1, mg/dL	124.3±29.7	109.4±26.2	0.014
Endotelial (dys) function markers
PAI-1, ng/mL	17.9 (12.3–30.4)	27.4 (14.2–46.9)	0.034
D-dimers, ng/mL	0.70 (0.40–1.29)	1.47 (0.63–2.28)	0.005
Nutritional markers
Body mass index, kg/m^2	25.4 (23.0–28.5)	23.3 (20.5–27.3)	0.008
Albumin, g/dL	4.00 (3.78–4.20)	3.70 (3.37–3.94)	<0.001

Data are presented as means and standard deviation or median (interquartile range). RDW: red blood cells distribution width; IL-6: interleukin-6; CRP: C-reactive protein; VLDL: very low-density lipoprotein; Apo A: apolipoprotein A; PAI-1: plasminogen activator inhibitor 1.